22.728 articles found

Parkinson's disease-associated fatigue: emerging new therapeutic options.

Kapoor S.

J Pain Symptom Manage · 2014-01-10

DOI: 10.1016/j.jpainsymman.2013.11.005PMID: 24417805

Gene therapy for Parkinson's disease: a step closer?

Stoessl AJ.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)62108-xPMID: 24412047

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.

Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefaucheur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Guzman NV, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA.

Lancet · 2014-01-10

DOI: 10.1016/s0140-6736(13)61939-xPMID: 24412048

Initiating levodopa therapy for Parkinson's disease.

Olanow CW, Kieburtz K, Stocchi F.

Mov Disord · 2014-01-09

DOI: 10.1002/mds.25805PMID: 24408661

A brief perspective on neural cell therapy.

Pruszak J.

Mol Cell Ther · 2014-01-08

PMID: 26056571

Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Sensi M, Preda F, Trevisani L, Contini E, Gragnaniello D, Capone JG, Sette E, Golfre-Andreasi N, Tugnoli V, Tola MR, Quatrale R.

J Neural Transm (Vienna) · 2014-01-08

DOI: 10.1007/s00702-013-1153-3PMID: 24398781

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.

Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R.

Biochem Pharmacol · 2014-01-07

DOI: 10.1016/j.bcp.2013.12.023PMID: 24406245

Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.

Müller T, Muhlack S.

J Neural Transm (Vienna) · 2014-01-05

DOI: 10.1007/s00702-013-1155-1PMID: 24390153

Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.

Ueno T, Yamada J, Nishijima H, Arai A, Migita K, Baba M, Ueno S, Tomiyama M.

Neurobiol Dis · 2014-01-04

DOI: 10.1016/j.nbd.2013.12.014PMID: 24398173

Correction: Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease

Check source for author details

PloS one · 2014-01-01

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

Stayte S, Vissel B.

Frontiers in neuroscience · 2014-01-01

Targeting the unfolded protein response as a potential therapeutic in prion disease

Halliday M.

· 2014-01-01